Loading
CB
CTI Biopharma Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Craig Adam R, was filed 16 Aug 2022.
CTI Biopharma Corp: what insiders have been doing
This page follows insider dealings at CTI Biopharma Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for CTI Biopharma Corp. The previous disclosure was published on 28 June 2023.
Our records for CTI Biopharma Corp go back to 2016, with 18 purchases and 135 sales on the open market in total.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
245
Thresholds
n/a
Buy Volume
€21M
18 ops. · all time
Sell Volume
€65M
135 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$46.4M
Net income-US$80.1M-172.4% margin
Last declaration on 28 June 2023
Declarations245 total
3,989,130 shares@ US$9.1059.0% of flowCommon Stock, par value $0.001SEC:0000921895-23-001602:0
2,595,239 shares@ US$9.1014.9% of flowCommon Stock, par value $0.001SEC:0000921895-23-001602:1
702,505 shares@ US$9.104.0% of flowCommon Stock, par value $0.001SEC:0000921895-23-001602:2
1,526,147 shares@ US$9.108.7% of flowCommon Stock, par value $0.001SEC:0000921895-23-001602:3
43,139 shares@ US$9.100.2% of flowCommon Stock, par value $0.001SEC:0000921895-23-001602:4
43,139 shares@ US$9.10100.0% of flowCommon StockSEC:0000899243-23-016484:0
48,639 shares@ US$9.10100.0% of flowCommon StockSEC:0000899243-23-016482:0
31,470 shares@ US$9.1039.8% of flowCommon StockSEC:0000899243-23-016480:0
17,547 shares@ US$9.1072.7% of flowCommon StockSEC:0000899243-23-016485:0
3,565 shares@ US$9.1025.4% of flowCommon StockSEC:0000899243-23-016479:0
100,000 shares@ US$6.0082.5% of flowcommon stockSEC:0000891293-23-000003:1
83,200 shares@ US$6.007.7% of flowcommon stockSEC:0000891293-23-000004:1
2,117 shares@ US$0.84110.0% of flowcommon stockSEC:0000891293-23-000004:2
2,117 shares@ US$6.010.2% of flowcommon stockSEC:0000891293-23-000004:3
83,200 shares@ US$0.84119.8% of flowcommon stockSEC:0000891293-23-000004:0
100,000 shares@ US$0.948974.6% of flowcommon stockSEC:0000891293-23-000003:0
13,800 shares@ US$6.001.3% of flowcommon stockSEC:0000891293-23-000002:1
1,579 shares@ US$5.10850.1% of flowcommon stockSEC:0000891293-23-000002:2
12,000 shares@ US$0.84110.2% of flowcommon stockSEC:0000891293-23-000002:3
12,000 shares@ US$6.001.1% of flowcommon stockSEC:0000891293-23-000002:4
700 shares@ US$0.84110.0% of flowcommon stockSEC:0000891293-23-000002:5
700 shares@ US$6.0050.1% of flowcommon stockSEC:0000891293-23-000002:6
4,400 shares@ US$0.84110.1% of flowcommon stockSEC:0000891293-23-000002:7
4,400 shares@ US$6.010.4% of flowcommon stockSEC:0000891293-23-000002:8
84,683 shares@ US$0.84111.1% of flowcommon stockSEC:0000891293-23-000002:9
25 of 245 declarations
About CTI Biopharma Corp
CTI BioPharma Corp. is a US biopharmaceutical company that built its franchise around targeted therapies for blood cancers, with a particular emphasis on myelofibrosis. Historically headquartered in Seattle, Washington, the company developed a profile as a specialist hematology-oncology player rather than a broad-based pharmaceutical group. It was listed in the United States on the Nasdaq market under the ticker CTIC before being acquired by Swedish Orphan Biovitrum AB (Sobi). The acquisition was announced in May 2023 and completed in June 2023, after which CTI BioPharma became an indirect subsidiary of Sobi. That history remains relevant for investors tracking legacy SEC filings and insider transaction activity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/d436727dex992.htm?utm_source=openai))
The company’s key commercial asset was VONJO® (pacritinib), an oral kinase inhibitor approved by the FDA in the United States for adults with intermediate- or high-risk primary or secondary myelofibrosis and severe thrombocytopenia. This approval was the defining value-creation event in CTI BioPharma’s corporate story, shifting the company from a development-stage biotechnology name to a commercial-stage hematology company. Prior to its acquisition, management’s core focus was on building awareness, physician adoption, and market penetration for VONJO in a highly specialized patient population with limited treatment options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, CTI BioPharma operated in a narrow but scientifically important niche. In myelofibrosis, treatment selection depends heavily on clinical benefit, tolerability, and the ability to serve patients with significant cytopenias. VONJO’s positioning was designed to address a population that is often underserved by broader therapies, which gave CTI BioPharma a differentiated commercial story even though it remained a relatively small player versus large hematology franchises. The company’s competitive appeal therefore came less from scale and more from asset specificity and clinical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai))
Geographically, CTI BioPharma’s operating footprint was centered in the United States. Its corporate base was in Seattle, and its commercial and regulatory execution was primarily tied to the US market. For French, Belgian, and Swiss investors, the key market identifiers are straightforward: the company was US-listed on Nasdaq and domiciled in the United States, with business activities concentrated in US hematology markets before the Sobi transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai))
Recent material developments are dominated by the strategic sale to Sobi, which followed the US launch and commercialization phase of VONJO. As a result, CTI BioPharma is best understood today as a case study in a focused biotech that successfully advanced a single lead asset into the market and then exited via acquisition. For SEO and investor-oriented content, the most relevant themes are its Seattle roots, Nasdaq history, FDA-approved product, specialization in myelofibrosis, and the 2023 acquisition by Sobi. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/d436727dex992.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
